What is the most recent earnings date for VERV stock?
VERVE THERAPEUTICS INC (VERV) last reported earnings on 5/14/2025.
NASDAQ:VERV • US92539P1012
Past quarterly earnings results for VERVE THERAPEUTICS INC (VERV), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.35 | -0.67 | 47.66% | 40.68% | 32.976M | 9.563M | 244.83% | 479.03% |
| Q4 2024 | -0.58 | -0.71 | 18.30% | 15.94% | 13.08M | 4.042M | 223.60% | 154.33% |
| Q3 2024 | -0.59 | -0.71 | 17.01% | 18.06% | 6.865M | 2.866M | 139.53% | 120.24% |
| Q2 2024 | -0.59 | -0.70 | 15.43% | 32.18% | 6.692M | 2.448M | 173.37% | 219.73% |
| Q1 2024 | -0.59 | -0.73 | 18.87% | 29.76% | 5.695M | 2.066M | 175.65% | 305.63% |
| Q4 2023 | -0.69 | -0.84 | 17.70% | -2.99% | 5.143M | 1.192M | 331.46% | 409.21% |
| Q3 2023 | -0.72 | -0.94 | 23.11% | 8.86% | 3.117M | 982.943K | 217.11% | 235.16% |
| Q2 2023 | -0.87 | -0.94 | 7.09% | -3.57% | 2.093M | 771.885K | 171.15% | - |
| Q1 2023 | -0.84 | -0.79 | -5.72% | -35.48% | 1.404M | 524.576K | 167.64% | - |
| Q4 2022 | -0.67 | -0.78 | 14.10% | -3.08% | 1.01M | - | - | |
| Q3 2022 | -0.79 | -0.75 | -5.27% | -68.09% | 930K | - | - | |
| Q2 2022 | -0.84 | -0.66 | -27.26% | 87.39% | - | - | ||
| Q1 2022 | -0.62 | -0.67 | 7.50% | - | - | - | ||
| Q4 2021 | -0.65 | -0.56 | -15.56% | - | - | - | ||
| Q3 2021 | -0.47 | -0.46 | -1.83% | - | - | - | ||
| Q2 2021 | -6.66 | -0.50 | -1,232.53% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
VERVE THERAPEUTICS INC (VERV) last reported earnings on 5/14/2025.
VERVE THERAPEUTICS INC (VERV) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, VERVE THERAPEUTICS INC (VERV) has beaten EPS estimates in 4 out of 4 releases.